EUR 14.6
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 8.39 Million GBP | 39.92% |
2022 | 6.07 Million GBP | 60.14% |
2021 | 3.79 Million GBP | 323.66% |
2020 | 896 Thousand GBP | 128.57% |
2019 | 392 Thousand GBP | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 5.16 Million EUR | 0.0% |
2023 Q4 | 4.11 Million EUR | 13.58% |
2023 FY | 8.5 Million GBP | 39.92% |
2023 Q2 | 3.62 Million EUR | 32.71% |
2022 Q4 | 2.73 Million EUR | 5.74% |
2022 FY | 6.07 Million GBP | 60.14% |
2022 Q2 | 2.58 Million EUR | 48.01% |
2021 Q2 | 2.05 Million EUR | 225.96% |
2021 FY | 3.79 Million GBP | 323.66% |
2021 Q4 | 1.74 Million EUR | -14.84% |
2020 Q2 | 383.94 Thousand EUR | 0.0% |
2020 FY | 896 Thousand GBP | 128.57% |
2020 Q4 | 628.98 Thousand EUR | 63.82% |
2019 FY | 392 Thousand GBP | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BioNTech SE | 2.52 Billion EUR | 99.668% |
CureVac N.V. | 211.75 Million EUR | 96.037% |
Biotest Aktiengesellschaft | 136.8 Million EUR | 93.865% |
Biotest Aktiengesellschaft | 136.8 Million EUR | 93.865% |
BRAIN Biotech AG | 24.94 Million EUR | 66.353% |
Formycon AG | 23.73 Million EUR | 64.64% |
Heidelberg Pharma AG | 27.81 Million EUR | 69.83% |
Medigene AG | 20.54 Million EUR | 59.143% |